Tier 2 — strong

Combined Metabolic Activators Accelerates Recovery in Mild-to-Moderate COVID-19

Altay O, Arif M, Li X, Yang H, Aydın M, Alkurt G, Kim W, Akyol D, Zhang C, Dinler-Doganay G, Turkez H, Shoaie S, Nielsen J, Borén J, Olmuscelik O, Doganay L, Uhlén M, Mardinoglu A
Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2021 8; 17; e2101222

Bibliography

PubMed
PMID 34180141
PubMed Central
PMC8420376
DOI
10.1002/advs.202101222
Funding
ScandiBio Therapeutics, Knut and Alice Wallenberg Foundation and EU research support; ChromaDex supplied NR.
Competing interests
Three authors were ScandiBio founders/shareholders and disclosed a patent application concerning the combination treatment.

Study snapshot

DesignRandomized controlled study of a multi-ingredient or combined intervention
ModelHuman participants
Sample93 participants in phase II and 304 in phase III
InterventionNR combined with serine, NAC and carnitine tartrate
DurationShort acute-infection treatment courses
EndpointsTime to symptom-free recovery; metabolic and inflammatory profiles

What the study showed, in plain terms

The four-ingredient combination shortened time to symptom-free recovery in the reported acute COVID-19 trials.

Key findings

The four-ingredient combination shortened time to symptom-free recovery in the reported acute COVID-19 trials.

What this study can and cannot tell us

The intervention cannot identify an NR-specific effect. Acute infection results do not establish efficacy for long COVID, prevention or current antiviral replacement.

Related papers in the corpus

Tier 2
Multi-omics characterization of improved cognitive functions in Parkinson's disease patients after the combined metabolic activator treatment: a randomized, double-blinded, placebo-controlled phase II trial
Yulug B et al. · Brain communications · 2025
Tier 2
Combined metabolic activators improve cognitive functions in Alzheimer's disease patients: a randomised, double-blinded, placebo-controlled phase-II trial
Yulug B et al. · Translational neurodegeneration · 2023
Tier 2
The acute effect of different NAD + precursors included in the combined metabolic activators
Li X et al. · Free radical biology & medicine · 2023
Tier 2
Combined metabolic activators therapy ameliorates liver fat in nonalcoholic fatty liver disease patients
Zeybel M et al. · Molecular systems biology · 2021

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology